Free shipping on all orders over $ 500

Pembrolizumab

Cat. No. M6102
Pembrolizumab Structure
Synonym:

Lambrolizumab; MK-3475;Keytruda

Size Price Availability Quantity
2mg USD 330  USD330 In stock
5mg USD 610  USD610 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Pembrolizumab is a potent, highly selective, fully humanized immunoglobulin (Ig) G4-kappa monoclonal antibody against PD-1 with potential immune checkpoint inhibitory and antineoplastic activities. The binding of PD-1 with pembrolizumab was located on the C'D loop of PD-1. MW : 146.286 KD.

In addition to Melanoma and Lung carcinoma, pembrolizumab has also demonstrated efficacy in other advanced solid tumors and hematologic malignancies. Pembrolizumab had an acceptable side-effect profile and showed antitumor activity in patients with advanced non-small-cell lung cancer.

Chemical Information
CAS Number 1374853-91-4
Storage -80°C for long term
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Minan Wang, et al. FASEB J. Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy

[2] Shuguang Tan, et al. Nat Commun. An unexpected N-terminal loop in PD-1 dominates binding by nivolumab

[3] Reck M, et al. N Engl J Med. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

[4] Faghfuri E, et al. Expert Rev Anticancer Ther. Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma.

[5] Barbee MS, et al. Ann Pharmacother. Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology.

[6] Garon EB, et al. N Engl J Med. Pembrolizumab for the treatment of non-small-cell lung cancer.

Related PD-1/PD-L1 Products
Rosnilimab

Rosnilimab is a novel PD-1 checkpoint agonist antibody that reduces overactive T cell inflammation. Rosnilimab optimizes PD-1+ T cell inhibitory signaling by enabling tight immune synapse formation. Rosnilimab restores immune balance bringing T cell composition to a less activated state.

Recombinant Anti-Mouse PD1 mAb

Recombinant Anti-Mouse PD1 mAb is a recombinant monoclonal antibody against the mouse PD1 protein, with the antibody isoform Mouse lgG1/lambda. the antibody efficiently binds to the mPD1 protein on the cell surface and significantly inhibits tumor growth in a mouse tumor model transplanted with MC38 cells. the antibody is used to detect the presence of the mouse PD1 protein on the cell surface of the cell. the antibody is used to detect the presence of the mouse PD1 protein on the cell surface of the cell.

Erfonrilimab

Erfonrilimab is a humanized single-domain bispecific antibody-Fc fusion protein (VH-VH-h-CH2-CH3 dimer) targeting the immune checkpoints PD-L1 and CTLA-4.

Benmelstobart

Benmelstobart is an anti-PD-L1 humanized IgG1ҡ monoclonal antibody that can be used for tumor-related studies.

Human PD-L1 inhibitor II

Human PD-L1 inhibitor II is a potent PD-L1 inhibitor with anti-cancer activity.

  Catalog
Abmole Inhibitor Catalog




Keywords: Pembrolizumab, Lambrolizumab; MK-3475;Keytruda supplier, PD-1/PD-L1, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.